Original title: Mathematical modelling of immune persistence and relapse pathways in CAR T-cell therapy for B-ALL
Alexis Farman, Benjamin J. Walker, Martin A. Pule, Karen M. Page · August 2026
CAR T-cell therapy alters a patient's immune cells to destroy a blood cancer called B-ALL. While it often works at first, the cancer frequently returns. This relapse happens when engineered immune cells vanish, cancer cells hide from detection, or hidden cancer sites shield them. Scientists know these living therapies must persist inside the body to keep patients healthy, but they did not know why. To find out, researchers built a mathematical simulation tracking cancer growth and three stages of immune cells. They discovered that two cell types block relapse differently. Long-lived memory cells maintain surveillance against slowly growing residual cancer. Meanwhile, active effector cells wipe out isolated cancer cells escaping from shielded hideouts. The simulation also showed a trade-off between quick killing and long-term protection.
Imagine a security team guarding a large building. They have two types of guards: some patrol the halls constantly, others respond quickly to alarms. If the patrolling guards stop walking, small suspicious activities go unnoticed. If the quick-response guards are not available, sudden break-ins from hidden corners succeed. In this paper, the patrolling guards correspond to memory CAR T-cells that watch for slow-growing residual disease, and the quick-response guards correspond to effector CAR T-cells that clear blasts emerging from immune-privileged sites.
For patients with B-cell acute lymphoblastic leukaemia, relapse after CAR T-cell therapy remains a major problem. This work explains why prolonged persistence of CAR T-cells is needed: memory cells watch for slow-growing disease, while effector cells attack hidden tumour cells. That distinction could help doctors tailor treatments to reduce relapse risk.
The model is calibrated against a single trial (FELIX) in adult B-ALL, so its predictions may not generalize to other CAR T-cell products or pediatric patients. It does not incorporate all known relapse mechanisms, such as CAR T-cell exhaustion or tumour microenvironment effects. The identified trade-offs and modifiable factors require experimental validation before clinical application.
Ask anything about this paper. Answers come from its abstract, and say so when the abstract doesn't cover your question.
Mathematical modelling of immune persistence and relapse pathways in CAR T-cell therapy for B-ALL — Alexis Farman, Benjamin J. Walker, Martin A. Pule et al.
Abstract licence: CC0
Explanation generated by Synthesis from the abstract — it is not the original paper. This is a preprint, so it hasn't necessarily been peer reviewed.